The importance of correction of anemia with erythropoietin and intravenous iron in severe resistant congestive heart failure

European Journal of Heart Failure, Supplement

Volumn 2, Issue 2, 2003, Pages 225-230

  Wexler, Dov ^a   Silverberg, Don ^a   Sheps, David ^a   Iaina, Adrian ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Anemia; Chronic kidney insufficiency (CKI); Congestive heart failure (CHF); Erythropoietin (EPO); Quality of life (QOL)

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ERYTHROPOIETIN; FERRIC SUCROSE; FUROSEMIDE; HEMOGLOBIN; IRON DERIVATIVE; NITRATE; RECOMBINANT ERYTHROPOIETIN; SPIRONOLACTONE; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CACHEXIA; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REDUCTION; ENDURANCE; EXERCISE; HEART LEFT VENTRICLE EJECTION FRACTION; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HOSPITALIZATION; HUMAN; IMMUNOPATHOGENESIS; IRON THERAPY; KIDNEY FAILURE; KIDNEY FUNCTION; LENGTH OF STAY; MALIGNANT NEOPLASTIC DISEASE; MALNUTRITION; MORTALITY; NONHUMAN; OXYGEN CONSUMPTION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; QUALITY OF LIFE; WEIGHT REDUCTION;

EID: 5644253519     PISSN: 15674215     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-4215(03)80008-5     Document Type: Article

References (55)

1. Cowie M.R., Mosterd A., Wood D.A., et al. The epidemiology of heart failure. Eur Heart J 18 (1997) 208-225
2. Juenger J., Schellberg D., Kraemer S., et al. Health related quality of life in patients with congestive heart failure: comparison with other chronic diseases and related functional variables. Heart 87 (2002) 235-241
3. Silverberg D.S., Wexler D., Blum M., et al. The use of subcutaneous Erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function, functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 35 (2000) 1737-1744
4. Cromie N., Lee C., and Struthers A.D. Anaemia in chronic heart failure: what is the frequency in the UK and its underlying cause?. Heart 87 (2002) 377-378
5. Tanner H., Moschovitis G., Kuster G.M., et al. The prevalence of anemia in chronic heart failure. Int J Cardiol 86 (2002) 115-121
6. Poole-Wilson P.A., Uretsky B.F., Thygesen K., Cleland J.G., Massie B.N., and Ryden L. Mode of death in heart failure: findings from the ATLAS trial. Heart 89 (2003) 42-48
7. Ezekowitz J.A., McAlister F.A., and Armstrong P.W. Anemia is common in heart failure and is associated with poor outcomes. Circulation 107 (2003) 223-225
8. Horwich T.B., Fonarow G.C., Hamilton M.A., MacLellan W.R., and Borenstein J. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol 39 (2002) 1780-1786
9. Chatterjee B., Nydegger U.E., and Mohacsi P. Serum erythropoietin in heart failure treated with ACE inhibitors or ATI antagonists. Eur J Heart Failure 2 (2000) 392-398
10. Wisniacki N., Aimson P., and Lyle M. Is anemia a cause of heart failure in the elderly?. Heart 85 Suppl I (2001) P4 (abstract)
11. McClellan W.M., Flanders W.D., Langston R.D., Jurkovitz C., and Presley R. Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study. J Am Soc Nephrol 13 (2002) 1928-1936
12. Kosiborod M., Smith G.L., Radford M.J., Foody J.M., and Krumholz H.M. The prognostic importance of anemia in patients with heart failure. Am J Med 114 (2003) 112-119
13. Androne A.-S., Katz S.D., Lund L., et al. Hemodilution is common in patients with advanced heart failure. Circulation 107 (2003) 226-229
14. Al-Ahmad A., Rand W.M., Manjunath G., et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 38 (2001) 955-962
15. Anker S.D., Sharma R., Fracis D., Pitt B., Poole-Wilson P.A., and Coats A.J.S. Anemia and survival in 3044 patients with Chronic Heart Failure (CHF) in the ELITE II Study. Circulation 106 (2002) 2335A (Abstract)
16. Alexander M., Grumbach K., Remy L., Rowell R., and Massie B.M. Congestive heart failure hospitalizations and survival in California: patterns according to race/ethnicity. Am Heart J 137 (1999) 919-927
17. Polanczyk C.A., Newton C., Dec G.C., and Di Salvo T.G. Quality of care hospital readmission in congestive heart failure: an explicit review process. J Cardiac Failure 7 (2001) 289-298
18. Carson J.L. Morbidity risk assessment in the surgically anemic patient. Am J Surg 170 Suppl 6A (1995) 32S-36S
19. Wahr J.A. Myocardial ischemia in anaemic patients. Br J Anaest 81 (1998) 10-15 (Suppl)
20. Packer M., Cohn J.N., et al. Consensus recommendations for the management of chronic heart failure. Am J Cardiol 83 (1999) 1-38A
21. Hunt S.A., Baker D.W., Chin M.C., et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure: executive summary. Circulation 104 (2001) 2996-3007
22. Silverberg D.S., Blum M., Peer G., Kaplan E., and Iaina A. Intravenous ferric saccharate as an iron supplement in dialysis patients. Nephron 72 (1996) 413-417
23. Macdougall I.C., Tucker B., Thompson J., Tomson C.R., Baker L.R., and Raine A.E. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 50 (1995) 1694-1699
24. Fishbane S., Frei G.L., and Maesaka J. Reduction in recombinant human Erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 26 (1995) 41-46
25. Silverberg D.S., Wexler D., Sheps D., et al. The effect of correction of mild anemia in severe resistant heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 37 (2001) 1775-1780
26. Silverberg D.S., Wexler D., Blum M., et al. The correction of anemia in severe resistant heart failure with erythropoietin and intravenous iron prevents the progression of both the heart and renal failure and markedly reduces hospitalization. Clin Nephrol 58 Suppl 1 (2002) S37-S45
27. Silverberg D.S., Wexler D., Blum M., et al. The effect of correction of anemia in diabetic and non diabetics with severe resistant congestive heart failure and chronic renal failure by subcutanous erythropoietin and intravenous iron. Nephrol Dial Transplant 18 (2003) 141-146
28. Mancini D.M., Katz S.D., Lang C., La Manca J., Hudaihed A., and Androne A.-S. Effect of Erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 107 (2003) 294-299
29. Tong E.M., and Nissenson A.R. Erythropoietin and anemia. Sem Nephrol 21 (2001) 190-203
30. Collins A.J. Influence of target hemoglobin in dialysis patients on morbidity and mortality. Kidney Int 61 Suppl 80 (2002) S44-S48
31. Moreno F., Sans-Guajardo D., Lopez-Gomez J.M., Jofre R., and Valderrabano F. Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. J Am Soc Nephrol 11 (2000) 335-542
32. St Peter W.L., Xue J., Ebben J., and Collins A. Pre-end stage renal disease erythropoietin use predicts hospitalization in the periods before and after end-stage renal disease diagnosis. J Am Soc Nephrol 12 (2001) 1274 Abstract
33. Holland D.C., and Lam M. Predictors of hospitalization and death among pre- dialysis patients: a retrospective cohort study. Nephrol Dial Transplant 15 (2000) 650-658
34. Levin A. The relationship of hemoglobin level and survival: direct or indirect effects. Neph Dial Transplant 17 Suppl 5 (2002) 8-13
35. Keane W.F., and Lyle P.A. Recent advances in management of type 2 diabetes and nephropathy: Lessons from the RENAAL Study. Am J Kidney Dis 41 Suppl 1 (2003) S22-S25
36. Aaparo M.S., Cella D., and Zagari M. Age, anemia and fatigue. Sem Oncol 29 Suppl 8 (2002) 55-59
37. Daneryd P. Epoetin Alpha for protection of metabolic and exercise capacity in cancer patients. Sem Oncol 29 Suppl 8 (2002) 69-74
38. Sharma R., and Anker S.D. From tissue wasting to cachexia: changes in peripheral blood flow and skeletal musculature. Eur Heart J Supp 4 Suppl D (2002) D12-D17
39. Trovato G.M., Catalano D., Vitale M., et al. Malnutrition and anemia in heart failure (CHF) without renal insufficiency. Nephrol Dialys Transpl 17 Suppl 1 (2002) T138
40. Carson J.L., Duff A., Poses R.M., et al. Effect of anaemia and cardiovascular disease on surgical mortality and morbidity. Lancet 348 (1996) 1055-1060
41. Wu W.-C., Rathore S.S., Wang Y., Radford M.J., and Krumholtz H. Blood transfusion in elderly patients with acute myocardial infarction. N Engl J Med 345 (2001) 1230-1236
42. Anand I.S., Chandrashekhar Y., Ferrari R., Poole-Wilson P.A., and Harris P.C. Pathogenesis of oedema in chronic anaemia: studies of body water and sodium, renal function, haemodynamics and plasma hormones. Br Heart J 70 (1993) 357-362
43. Johnson D.B., and Dell'Italia L.J. Cardiac hypertrophy and failure in hypertension. Curr Opin Nephrol Hypertension 5 (1996) 186-191
44. Katz A.M. The cardiomyopathy of overload: An unnatural growth response in the hypertrophied heart. Ann Intern Med 121 (1994) 363-371
45. Siems W.G., Sommerburg O., and Grune T. Erythrocyte free radical and energy formation. Clin Nephrol 53 Suppl 1 (2000) S9-S17
46. Grune T., Sommerburg O., and Siems W.G. Oxidative stress in anemia. Clin Nephrol 53 Suppl 1 (2000) S18-S22
47. Kristal B., Shurtz-Swirski R., Shasha S.M., et al. Interaction between erythropoietin and peripheral polymorphonuclear leukocytes in hemodialysis patients. Nephron 81 (1998) 406-413
48. Fine L., Dandyopadhay D., and Norman J.T. Is there a common mechanism for the progression of different types of renal diseases other than proteinuria? Towards the unifying theme of chronic hypoxia. Kidney Int 57 Suppl 75 (2000) S22-S26
49. Iverson P.O., Woldbaek P.R., Tonnessen T., and Christensen G. Decreased hematopoiesis in bone marrow of mice with congestive heart failure. Am J Physiol Regul Integr Comp Physiol 282 (2002) R166-R172
50. Herrera-Garza E.H., Stetson S.J., Cubillos-Garzon A., Vooltich M.T., Farmer J.A., and Rorre-Amione G. Tumor necrosis factor. A mediator of disease progression in the failing human heart. Chest 115 (1999) 1170-1174
51. Means R.T. Advances in the anemia of chronic disease. Int J Hematol 70 (1999) 7-12
52. Macdougall I.C. The role of ACE inhibitors and angiotensin II receptor blockers in the response to erythropoietin. Nephrol Dial Transplant 14 (1999) 1836-1841
53. Vaziri N.D. Erythropoietin and Transferrin metabolism in nephrotic syndrome. Am J Kidney Dis 38 (2001) 1-8
54. NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. National Kidney Foundation - Dialysis Outcomes Quality Initiative. Am J Kidney Dis 30 (1997) S192-S240
55. Kratz A., and Lewandrowski K.B. Normal reference laboratory values. N Engl J Med 339 (1998) 1063-1072